• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

    4/8/24 7:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email

    Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities

    PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.

    IdeeLab Joins the Ginkgo Technology Network to Provide
Agriculture Companies in Brazil with End-to-End Product
Development & Manufacturing Service

    The Ginkgo Technology Network is a groundbreaking global ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs. Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.

    IdeeLab is leading sustainable agriculture biological products development in Brazil by developing new technologies on behalf of customers for the crop input market. Particularly noteworthy, in Q1 2025, IdeeLab will have the only plant in Brazil certified by regulators to make ag input metabolites and proteins from GMOs, which will enable next-generation products in agriculture, such as metabolite and peptide/protein-based biocontrol products that are potentially safer and more efficacious versus conventional chemicals. The manufacturing facility will eventually reach 6 million liters of fermentation capacity, which is more than enough to enable clients to do commercial derisking before potentially building out fermentation capacity of their own. 

    IdeeLab's biotech platforms, pilot-scale facility and industrial setting will complement Ginkgo's cell engineering and discovery capabilities. With IdeeLab, customers can now work with Ginkgo in various capacities such as metabolite and microbial discovery through fermentation scale up, registration, field trialing, and manufacturing a product in the fast-growing Brazilian biologicals market.

    Ginkgo will continue to add partners to the Technology Network to further complement its offerings, and enable more clients in Brazil to access and explore the joint capabilities of the integrated Technology Network. Ginkgo is already working with leading product developers in the Brazilian market, and more are expected to join with this new expansion.

    Ronaldo José Durigan Dalio, CEO of IdeeLab: "This partnership with Ginkgo will help us leap into the future, and leverages both companies to deliver even more innovative solutions to the Brazilian market in a faster and more efficient way. IdeeLab has been leading the development of the next generation of bio ag input in Brazil, and connecting GInkgo's expertise to ours in this process will also help us explore new routes for improving both industrial production and product field performance for our clients."

    Anna Marie Wagner, Ginkgo's SVP, Head of AI and Corporate Development: "IdeeLab has been inspiring a new era in Brazilian agriculture and we're thrilled to welcome them to the Ginkgo Technology Network! Adding IdeeLab to our network now gives us the complete, end-to-end ability to deliver ag biological products for customers, especially next-generation products that are based on proteins, peptides and metabolites."

    About IdeeLab Biotechnology 

    IdeeLab is a fast-growing innovative ag biotechnology company in Brazil, focused on developing disruptive biological technologies and products for sustainable and regenerative agriculture, including biocontrol of pests and diseases, induction of plant resistance/tolerance responses,biostimulation, nutritional cycling and modulation of biotic/abiotic stress in major crops. Our multidisciplinary approach enables us to address emerging needs of the global agriculture market, providing biotechnology-as-a-service along different stages of R&D, from Bioprospection and Discovery, to Agronomical Validation and Go-to-Market (scale up, formulation, shelf-life/quality control, technology transfer, and manufacturing). Our expertise in phytopathology, plant physiology, and biochemistry, and our laboratories and bioprocess facilities are tailored to serve the development of ag inputs based on microbial cell growth/spore titers, as well as metabolites, peptides/proteins, interference RNA, CRISPR-edited, and other GM-derived microorganisms. We are expanding these capabilities to an industrial setting dedicated exclusively to B2B production (white label), to be inaugurated at the end of 2024. For more information, visit www.ideelab.com.br, or follow us on social media channels Instagram

    (@ideelab_biotech) and LinkedIn (www.linkedin.com/company/ideelabbr/).

    IDEELAB BIOTECHNOLOGY CONTACT:

    [email protected]

    About Ginkgo Bioworks

    Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

    GINKGO BIOWORKS INVESTOR CONTACT:

    [email protected]

    GINKGO BIOWORKS MEDIA CONTACT:

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideelab-joins-the-ginkgo-technology-network-to-provide-agriculture-companies-in-brazil-with-end-to-end-product-development--manufacturing-service-302109679.html

    SOURCE IdeeLab Biotechnology

    Get the next $DNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    SEC Filings

    View All

    SEC Form EFFECT filed by Ginkgo Bioworks Holdings Inc.

    EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    8/15/25 12:15:24 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Ginkgo Bioworks Holdings Inc.

    S-3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    8/7/25 5:12:02 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.

    10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    8/7/25 5:05:04 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

    BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously required massive platform investments by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service that could help scientists design better drugs with fewer resources.

    8/20/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Second Quarter 2025 Fina

    8/7/25 5:01:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Coen Steven P. converted options into 2,547 shares and sold $10,669 worth of shares (1,084 units at $9.84), increasing direct ownership by 16% to 10,679 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    7/21/25 4:28:30 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Potter Myrtle S converted options into 10,822 shares (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    6/13/25 4:24:04 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hannan Kathy Hopinkah converted options into 10,822 shares, increasing direct ownership by 259% to 15,003 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    6/13/25 4:19:19 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ginkgo Bioworks downgraded by BTIG Research

    BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

    5/15/24 7:33:13 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by William Blair

    William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

    5/10/24 7:33:29 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by Raymond James with a new price target

    Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

    11/14/23 9:04:22 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/16/24 5:08:50 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/14/24 5:16:23 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/4/24 11:56:06 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Second Quarter 2025 Fina

    8/7/25 5:01:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgob

    7/31/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports First Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

    5/6/25 5:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

    BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting

    5/21/25 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

    Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

    5/14/24 6:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care